Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo, São Paulo, 05508-000, Brazil.
Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Biometals. 2019 Aug;32(4):707-715. doi: 10.1007/s10534-019-00202-7. Epub 2019 Jun 1.
The hydroxamate class of compounds is well known for its pharmacological applications, especially in the context of chelation therapy. In this work we investigate the performance of the fungal hydroxamates pyridoxatin (PYR), desferriastechrome (DAC) and desferricoprogen (DCO) as mitigators of stress caused by iron overload (IO) both in buffered medium and in cells. Desferrioxamine (DFO), the gold standard for IO treatment, was used as comparison. It was observed that all the fungal chelators (in aqueous medium) or PYR and DAC (in cells) are powerful iron scavengers. However only PYR and DCO (in aqueous medium) or PYR (in cells) were also antioxidant against two forms of iron-dependent oxidative stress (ascorbate or peroxide oxidation). These findings reveal that PYR is an interesting alternative to DFO for iron chelation therapy, since it has the advantage of being cell permeable and thus potentially orally active.
羟胺类化合物以其药理学应用而闻名,特别是在螯合疗法方面。在这项工作中,我们研究了真菌羟胺类化合物吡哆醇(PYR)、去铁胺(DAC)和去铁丙氨酸(DCO)作为铁过载(IO)应激缓解剂的性能,无论是在缓冲介质中还是在细胞中。去铁胺(DFO),IO 治疗的金标准,被用作比较。结果表明,所有真菌螯合剂(在水介质中)或 PYR 和 DAC(在细胞中)都是强大的铁清除剂。然而,只有 PYR 和 DCO(在水介质中)或 PYR(在细胞中)对两种形式的铁依赖性氧化应激(抗坏血酸或过氧化物氧化)具有抗氧化作用。这些发现表明,PYR 是 DFO 用于铁螯合疗法的一个有趣替代品,因为它具有细胞通透性的优势,因此具有潜在的口服活性。